Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Cohort A: Completion of 30 months of study treatment on Pfizer Protocol B3461028~Cohort B: Patients in specific countries diagnosed with ATTR-CM who did not previously participate in Pfizer Study B3461028~Exclusion Criteria:~-Liver and/or heart transplant, or implanted cardiac mechanical assist device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tafamidis (Type: EXPERIMENTAL): Active treatment - 61 mg or if not available, tafamidis megulmine 80 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).